Acasti Pharma Accounts Receivables 2011-2026 | ACST

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Acasti Pharma

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	802 K	548 K	530 K	546 K	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
802 K	530 K	606 K

Quarterly Accounts Receivables Acasti Pharma

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	398 K	-	959 K	837 K	837 K	802 K	778 K	859 K	964 K	548 K	238 K	813 K	448 K	530 K	619 K	625 K	495 K	546 K	-	-	-	1.19 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.19 M	238 K	694 K

Accounts Receivables of other stocks in the Biotechnology industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
Altimmune ALT	544 K	$ 4.2	-2.67 %	$ 298 M	USA
Apellis Pharmaceuticals APLS	366 M	$ 20.24	-3.44 %	$ 2.55 B	USA
Aptorum Group Limited APM	62.2 K	$ 0.8	1.87 %	$ 4.36 M	China
Aptevo Therapeutics APVO	5.22 M	$ 7.2	-1.64 %	$ 1.99 M	USA
I-Mab IMAB	130 M	-	-	$ 866 M	China
Aquestive Therapeutics AQST	7.34 M	$ 4.1	2.37 %	$ 356 M	USA
AgeX Therapeutics AGE	57 K	-	-10.17 %	$ 12.2 K	USA
Arcturus Therapeutics Holdings ARCT	3.97 M	$ 8.35	1.46 %	$ 225 M	Israel
Ardelyx ARDX	71.8 M	$ 6.37	-2.75 %	$ 1.54 B	USA
Armata Pharmaceuticals ARMP	25 K	$ 10.91	1.58 %	$ 394 M	USA
Arcutis Biotherapeutics ARQT	146 M	$ 25.33	-6.1 %	$ 3.22 B	USA
Arvinas ARVN	1 M	$ 12.97	-2.3 %	$ 920 M	USA
Arrowhead Pharmaceuticals ARWR	6.82 M	$ 61.74	-2.42 %	$ 8.26 B	USA
Atossa Therapeutics ATOS	298 K	$ 4.39	-0.9 %	$ 553 M	USA
Atara Biotherapeutics ATRA	1.48 M	$ 5.01	-7.47 %	$ 37.5 M	USA
Aurinia Pharmaceuticals AUPH	41.5 M	$ 14.14	-0.21 %	$ 1.9 B	Canada
Acorda Therapeutics ACOR	17.3 M	-	-24.86 %	$ 820 K	USA
Autolus Therapeutics plc AUTL	109 K	$ 1.68	-1.75 %	$ 429 M	Britain
Adverum Biotechnologies ADVM	886 K	-	-	$ 86.2 M	USA
AIkido Pharma AIKI	200 K	-	1.93 %	$ 17.4 M	USA
Albireo Pharma ALBO	3.27 M	-	-0.23 %	$ 916 M	USA
Axon Enterprise AXON	18.1 M	$ 570.5	5.18 %	$ 43.2 B	USA
Axsome Therapeutics AXSM	224 M	$ 162.28	-0.98 %	$ 8.07 B	USA
Aytu BioScience AYTU	31.2 M	$ 2.56	-0.58 %	$ 16.1 M	USA
Alpine Immune Sciences ALPN	392 K	-	-	$ 2.17 B	USA